Related Experiment Video
Updated: Jan 11, 2026

A High Resolution Method to Monitor Phosphorylation-dependent Activation of IRF3
Published on: January 24, 2016
DNA fragmentation factor B suppresses interferon to enable cancer persister cell regrowth
August F Williams1, David A G Gervasio1, Claire E Turkal1
1Department of Dermatology, School of Medicine, University of California San Diego, La Jolla, CA, USA.
Abstract:
Oncogene-targeted cancer therapies can provide deep responses but frequently suffer from acquired resistance. Therapeutic approaches to treat tumours that have acquired drug resistance are complicated by continual tumour evolution and multiple co-occurring resistance mechanisms. Rather than treating resistance after it emerges, it may be possible to prevent it by inhibiting the adaptive processes that initiate resistance, but these are poorly understood. Here we report that residual cancer persister cells that survive oncogene-targeted therapy are growth arrested by drug stress-induced intrinsic type I interferon signalling. To escape growth arrest, persister cells leverage apoptotic machinery to transcriptionally suppress interferon-stimulated genes (ISGs). Mechanistically, persister cells sublethally engage apoptotic caspases to activate DNA endonuclease DNA fragmentation factor B (also known as caspase-activated DNase), which induces DNA damage, mutagenesis and stress response factor activating transcription factor 3 (ATF3). ATF3 limits activator protein 1-mediated ISG expression sufficiently to allow persister cell regrowth. Persister cells deficient in DNA fragmentation factor B or ATF3 exhibit high ISG expression and are consequently unable to regrow. Therefore, sublethal apoptotic stress paradoxically promotes the regrowth of residual cancer cells that survive drug treatment.
Insights
Cancer therapies face resistance. Residual cancer cells survive treatment by suppressing immune signals, paradoxically using cell death pathways to regrow, complicating treatment strategies.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Acquired resistance is a major challenge in oncogene-targeted cancer therapies, leading to treatment failure.
- Tumour evolution and multiple resistance mechanisms complicate therapeutic strategies for resistant cancers.
- Understanding adaptive processes that initiate resistance is crucial for developing preventative strategies.
Purpose of the Study:
- To investigate the mechanisms by which residual cancer persister cells survive oncogene-targeted therapy.
- To elucidate the role of drug stress-induced signaling in persister cell growth arrest and escape.
- To identify potential targets for preventing acquired drug resistance.
Main Methods:
- Analysis of residual cancer persister cells surviving oncogene-targeted therapy.
- Investigating the role of type I interferon signaling in drug stress-induced growth arrest.
- Utilizing genetic manipulation to assess the function of apoptotic machinery components (caspases, DNA fragmentation factor B, ATF3) in persister cell regrowth.
- Measuring interferon-stimulated gene (ISG) expression and DNA damage in persister cells.
Main Results:
- Residual cancer persister cells are growth arrested by drug stress-induced type I interferon signaling.
- Persister cells suppress interferon-stimulated genes (ISGs) to escape growth arrest by leveraging apoptotic machinery.
- Sublethal engagement of apoptotic caspases activates DNA fragmentation factor B, leading to DNA damage and ATF3 induction.
- ATF3 suppresses ISG expression, enabling persister cell regrowth; deficiency in DNA fragmentation factor B or ATF3 prevents regrowth due to high ISG expression.
Conclusions:
- Sublethal apoptotic stress paradoxically promotes the regrowth of residual cancer cells that survive drug treatment.
- Targeting the interplay between apoptotic pathways and interferon signaling may offer strategies to overcome acquired resistance.
- Understanding persister cell adaptive mechanisms is key to developing more effective and durable cancer therapies.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
10:49A Murine Cell Line Based Model of Chronic CDK9 Inhibition to Study Widespread Non-Genetic Transcriptional Elongation Defects TEdeff in Cancers
Published on: September 26, 2019
Related Concept Videos
Abnormal Proliferation
Negative Regulator Molecules
Restarting Stalled Replication Forks
The Intrinsic Apoptotic Pathway
DNA Damage can Stall the Cell Cycle
DNA Damage Can Stall the Cell Cycle